Early Phase 1 N=79 Perceptual-motor Interaction to Improve Bimanual Coordination After Stroke
Stroke
Primary: Maximum Cross-correlation Coefficient — 0.989; 0.945; 0.995; 0.996 cross-correlation coefficient — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=343 GeoScan and Remote Geo Smoking Study: Neural and Behavioral Correlates of Smokers' Exposure to Retail Environments
Smoking, Tobacco · Smoking · Smoking, Cigarette
Primary: Self-reported Cigarette Craving During the Experimental Manipulation Period — 48.33; 49.14; 47.17 units on a scale — p=0.74
N/A N=24 Altitudes for Caregivers
Care Burden · Care Giving Burden · Caregiver Burnout
Primary: Qualitative Summaries of Participant Experience in Post-Treatment Feedback — 17; 17; 14; 9 Participants
N/A N=37 eMOTION Formative Study
Physical Inactivity · Overweight or Obesity · Cancer
Primary: Safety Benchmark: Percentage of Participants Experiencing an Adverse Event — 0; 0; 0; 0 Participants
Phase 3 N=28 EEG Synchronized TMS Trial for Depression
Depression
Primary: Remission Rate — 2; 3 Participants — p=0.6
N/A N=44 Transcranial Direct Current Stimulation Therapy for Bipolar Depression
Depression, Bipolar · Bipolar Disorder · Mood Disorders
Primary: Number of Participants With Clinical Response [ Time Frame: At 6 Weeks Following Course of tDCS Treatment ] — 34 Participants
Phase 1 N=25 A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).
Idiopathic Pulmonary Fibrosis
Primary: 1_Subjects With Adverse Event (AE); Non-Serious AEs and Serious AEs — 0; 0; 1; 0 Participants
N/A N=26 Soft Exosuits for Functional Gait Recovery in Acute Stroke Rehabilitation
Stroke · Acute Stroke
Primary: Change in 10 Meter Walk Test — 0.48; 0.53; 0.78 m/sec
N/A N=1,230 Scaling Up Maternal Mental Healthcare by Increasing Access to Treatment (SUMMIT)
Perinatal Depression
Primary: Depressive Symptoms: Edinburgh Postnatal Depression Scale (EPDS) Mean Score — 9.27; 8.91; 9.15; 8.92 score on a scale — p=<0.05
Phase 1 N=16 Study to Evaluate the AIO-001 in Healthy Participants
Respiratory Disease
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 5; 6 Participants
Phase 2 N=24 Tariquidar-ondansetron Combination in Neuropathic Pain
Neuropathic Pain
Primary: Concertation-time Profile of Ondansetron in Plasma, Measured by the Area Under the Concentration-time Curve (AUC) — 0.89; 0.87 mg*hr/L — p=0.8651
Phase 2 N=36 Cannabidiol in Youth Alcohol Use Disorder
Alcohol Use Disorder
Primary: Concentrations of Glx (i.e., Glutamate + Glutamine) — 18.76; 18.57 mmol/kg — p=0.33
N/A N=39 Analysis of Balance and Functional Hop Tests in Athletes With Lower Extremity Injuries by Dual Task Study
Athletic Injuries · Knee Injuries · Ankle Injuries
Primary: Balance Performance Measurement (OSI-injured/Worse Side-Single Task) — 1.684; 2.300 score on a scale
Phase 3 N=728 Long Term Extension Study of Tapinarof Cream, 1% for Subjects With Atopic Dermatitis
Atopic Dermatitis
Primary: Number of Subjects With Treatment-Emergent Adverse Events (TEAE) and Serious Adverse Events — 451; 34 Participants
N/A N=115 Evaluation of an Artificial Intelligence-Assisted, Image-Based Dietary Assessment Tool in the Framingham Heart Study
Dietary Habits
Primary: Acceptability of Dietary Assessment Method — 3.3; 3.1 units on a scale